Grigoroudis Asterios I, McInnes Campbell, Premnath Padmavathy Nandha, Kontopidis George
Institute for Research and Technology-Thessaly (I.RE.TE.TH.) Centre for Research & Technology Hellas (CE.R.TH.), 95 Dimitriados & Pavlou Mela Street, GR 38333, Volos, Greece; Laboratory of Biochemistry, Faculty of Veterinary Science, University of Thessaly, GR-43100 Karditsa, Greece.
Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, SC 29208, United States.
Protein Expr Purif. 2015 Sep;113:8-16. doi: 10.1016/j.pep.2015.01.013. Epub 2015 May 6.
Bacterial expression of human proteins continues to present a critical challenge in protein crystallography and drug design. While human cyclin A constructs have been extensively characterized in complex with cyclin dependent kinase 2 (CDK2), efforts to express the monomeric human cyclin A2 in Escherichia coli in a stable form, without the kinase subunit, have been laden with technical difficulties, including solubility, yield and purity. Here, optimized conditions are described with the aim of generating for first time, sufficient quantities of human recombinant cyclin A2 in a soluble and active form for crystallization and ligand characterization purposes. The studies involve implementation of a His-tagged heterologous expression system under conditions of auto-induction and mediated by molecular chaperone-expressing plasmids. A high yield of human cyclin A2 was obtained in natively folded and soluble form, through co-expression with groups of molecular chaperones from E. coli in various combinations. A one-step affinity chromatography method was utilized to purify the fusion protein products to homogeneity, and the biological activity confirmed through ligand-binding affinity to inhibitory peptides, representing alternatives for the key determinants of the CDK2 substrate recruitment site on the cyclin regulatory subunit. As a whole, obtaining the active cyclin A without the CDK partner (referred to as monomeric in this work) in a straightforward and facile manner will obviate protein--production issues with the CDK2/cyclin A complex and enable drug discovery efforts for non-ATP competitive CDK inhibition through the cyclin groove.
在蛋白质晶体学和药物设计中,人类蛋白质的细菌表达仍然是一个关键挑战。虽然人类细胞周期蛋白A构建体已与细胞周期蛋白依赖性激酶2(CDK2)形成复合物并得到广泛表征,但在大肠杆菌中以稳定形式表达不含激酶亚基的单体人类细胞周期蛋白A2的努力却充满了技术难题,包括溶解性、产量和纯度等问题。本文描述了优化条件,旨在首次获得足够数量的可溶且有活性的人类重组细胞周期蛋白A2,用于结晶和配体表征。这些研究涉及在自动诱导条件下实施带有组氨酸标签的异源表达系统,并由表达分子伴侣的质粒介导。通过与来自大肠杆菌的各种组合的分子伴侣组共表达,以天然折叠和可溶形式获得了高产率的人类细胞周期蛋白A2。采用一步亲和层析法将融合蛋白产物纯化至均一性,并通过与抑制肽的配体结合亲和力证实了其生物活性,这些抑制肽代表了细胞周期蛋白调节亚基上CDK2底物招募位点关键决定因素的替代物。总体而言,以直接简便的方式获得不含CDK伴侣的活性细胞周期蛋白A(在本文中称为单体)将避免CDK2/细胞周期蛋白A复合物的蛋白质生产问题,并有助于通过细胞周期蛋白凹槽进行非ATP竞争性CDK抑制的药物发现工作。